Myeloma survival statistics

Survival

Survive myeloma for 10 or more years, 2010-11, England and Wales

Age

Age that myeloma survival is highest, 2009-2013, England

 

Improvement

Myeloma survival in the UK has quadrupled in the last 40 years

 

78% of men survive myeloma for at least one year, and this is predicted to fall to 50% surviving for five years or more, as shown by age-standardised Open a glossary item net survival  for patients diagnosed with myeloma during 2010-2011 in England and Wales.[1] Survival for women is slightly lower, with 75% surviving for one year or more, and 44% predicted to survive for at least five years.

Myeloma (C90), Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 2010-2011

1-Year Survival (%) 5-Year Survival (%) 10-Year Survival (%)
Men Net Survival 77.9 49.8 36.6
95% LCL 77.9 49.3 34.8
95% UCL 78.0 50.3 38.4
Women Net Survival 75.1 43.8 28.1
95% LCL 75.1 43.0 25.3
95% UCL 75.2 44.5 30.9
Adults Net Survival 76.6 47.0 32.5
95% LCL 76.6 46.5 31.0
95% UCL 76.6 47.4 34.1

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item

Five- and ten-year survival is predicted using an excess hazard statistical model

Myeloma survival continues to fall beyond five years after diagnosis. 37% of men and 28% of women are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with myeloma during 2010-2011 in England and Wales.[1] Out of 20 common cancers in England and Wales, ten-year survival for myeloma ranks 6th lowest overall.

Myeloma (C90), Net Survival up to Ten Years after Diagnosis, Adults (Aged 15-99), England and Wales, 2010-2011

Survival for myeloma is reported in Scotland and Northern Ireland,[2,3] though it is difficult to make survival comparisons between countries due to different methodologies and criteria for including patients in analyses. An analysis of patients diagnosed with myeloma during 1991-1999 suggests all four UK countries have similar survival.[4]

See also

Cancer survival statistics for common cancers in the UK

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request, 2014. 
  2. ISD Scotland. Trends in Cancer Survival 1983-2007. 
  3. Northern Ireland Cancer Registry. Incidence & Survival 1993-2012. 
  4. Woods LM, Rachet B, Shack L, et al. Survival from twenty adult cancers in the UK and Republic of Ireland in the late twentieth century. Health Stat Q 2010;(46):5-24.

About this data

Data is for: England and Wales, 2010-2011, ICD-10 C90

Last reviewed:

Five-year survival for myeloma decreases with increasing age. Five-year net survival in men ranges from 74% in 15-49 year-olds to 24% in 80-99 year-olds for patients diagnosed with myeloma in England during 2009-2013.[1] In women, five-year survival ranges from 74% to 26% in the same age groups.

Older myeloma patients may be in poorer general health, so considered ineligible for transplants and unable to tolerate strong or sustained chemotherapy, which may explain their lower survival.[2,3]

Myeloma (C90), Five-Year Net Survival by Age, England, 2009-2013

See also

Myeloma incidence statistics by age

Myeloma mortality statistics by age

Cancer survival statistics by age for all cancers in the UK

References

  1. Office for National Statistics. Cancer survival in England: adults diagnosed in 2009 to 2013, followed up to 2014. Newport: ONS; 2015.
  2. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Reviews 2011;25(2):65-73. 
  3. Augustson BM, Begum G, Dunn JA, et al. Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23(36):9219-26.

About this data

Data is for: England, 2009-2013, ICD-10 C90

Last reviewed:

As with most cancers, survival for myeloma is improving. Some of the increase is likely to be attributable to earlier diagnosis and better detection,[1] though improvements since the early 1990s probably reflect the effective and widespread use of high-dose chemotherapy and autologous stem cell transplantation from the mid-1980s onwards.

One-year age-standardised Open a glossary item net survival for myeloma in men has increased from 37% during 1971-1972 to 78% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 41 percentage points.[2] In women, one-year survival has increased from 38% to 75% over the same time period (a difference of 37 percentage points).

Myeloma (C90), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year age-standardised net survival for myeloma in men has increased from 12% during 1971-1972 to a predicted survival of 50% during 2010-2011 in England and Wales – an absolute survival difference of 38 percentage point.[2] In women, five-year survival has increased from 11% to 44% over the same time period (a difference of 32 percentage points).

Myeloma (C90), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year survival has increased by a lesser amount than one- and five-year survival since the early 1970s. Ten-year age-standardised net survival for myeloma in men has increased from 7% during 1971-1972 to a predicted survival of 37% during 2010-2011 in England and Wales – an absolute survival difference of 29 percentage points.[2] In women, ten-year survival has increased from 6% to 28% over the same time period (a difference of 23 percentage points). Overall, a third of people diagnosed with myeloma today are predicted to survive their disease for at least ten years.

Myeloma (C90), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

Myeloma survivors may experience long-term consequences of their disease and side effects of the treatments they receive for it, including peripheral neuropathy, blood clots and gastrointestinal problems.[3] Accordingly, as survival rates improve, supportive care will play an increasingly vital role in myeloma management.

See also

Myeloma incidence trends over time

Myeloma mortality trends over time

Cancer survival statistics for common cancers in the UK

References

  1. Renshaw C, Ketley N, Møller H, et al. Trends in the  incidence and survival of multiple myeloma in South East England 1985-2004.  BMC Cancer 2010;10:74.
  2. Data were provided by London School of Hygiene and Tropical  Medicine on request, 2014.
  3. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for  supportive care in multiple myeloma 2011. Brit J Haematol  2011;154(1):76-103.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C90

Last reviewed:

The most recent England-wide data for 2004-2006 showed three-year survival rates were significantly lower in the most deprived areas than in the most affluent (41.1% versus 49.4% for men, 39.6% versus 47.5% for women).[1] However, a similar study from Scotland for 1996-2000 did not find any differences in survival by deprivation.[2]

See also

Find out more about the counting and coding of this data

Myeloma incidence statistics by socio-economic group

Cancer survival statistics by socio-economic group

References

  1. Rachet B, Ellis L, Maringe C, et al. Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Brit J Cancer 2010;103(4):446-53. 
  2. Shack LG, Rachet B, Brewster DH, et al. Socioeconomic inequalities in cancer survival in Scotland 1986–2000. Brit J Cancer 2007;97(7):999-1004.
Last reviewed:

The most recent five-year survival data for 1995-1999 show England is slightly below the average for Europe, while Scotland, Wales and Northern Ireland are around the European average.[1] Across the European countries, five-year survival rates range from 23.1% to 46.7%. However, as with international incidence estimates, differing data collection practices throughout Europe may contribute to the ranking of individual countries.

See also

Find out more about the counting and coding of this data

Myeloma incidence statistics in Europe and worldwide

Myeloma mortality statistics in Europe and worldwide

Worldwide cancer statistics

References

  1. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4.  Survival of cancer patients diagnosed in 1995-1999. Results and commentary.  Eur J Cancer 2009;45(6):931-91.
Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Rate this page:

Currently rated: 2.6 out of 5 based on 13 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page